Pamapimod

Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1].

Product Specifications

CAS Number

[449811-01-2]

Product Name Alternative

Ro4402257; R1503

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; p38 MAPK

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Pamapimod.html

Purity

99.92

Solubility

DMSO : ≥ 34 mg/mL

Smiles

O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC(CCO)CCO)N=C3N1C

Molecular Formula

C19H20F2N4O4

Molecular Weight

406.38

Precautions

H302, H315, H319, H335

References & Citations

[1]Hill, R. J. et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. The Journal of pharmacology and experimental therapeutics 327, 610-619, doi:10.1124/jpet.108.139006 (2008) .